Publications

Highlights

Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine.
Frontiers in Pharmacology, 27 November 2023.

A pilot study of cerebral metabolism and serotonin 5-HT2A receptor occupancy in rats treated with the psychedelic tryptamine DMT in conjunction with the MAO inhibitor harmine
Frontiers in Pharmacology, 28 September 2023.

Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial
eClinicalMedicine, February 2023.

Pharmacokinetic and Pharmacodynamic Interaction of the Ayahuasca Constituents Harmine and Dimethyltryptamine (DMT) in the Rat Brain
OSF Preprints, 10 December 2022.

Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey
PLOS Global Public Health, 16 November 2022.

Dexmedetomidine in Psychiatry: Repurposing of its Fast-Acting Anxiolytic, Analgesic and Sleep Modulating Properties
Pharmacopsychiatry, 16 November 2022.

Psychedelic Medicines: A Paradigm Shift from Pharmacological Substitution Towards Transformation-Based Psychiatry
Ayahuasca Healing and Science, 16 April, 2021.

Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers
Journal of Affective Disorders Reports, April 2021.

Impaired glutamate homeostasis in the nucleus accumbens in human cocaine addiction
Molecular Psychiatry, 28 June 2020.

Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat
Scientific Reports, 24 October 2019.

Effect of psilocybin on empathy and moral decision-making
International Journal of Neuropsychopharmacology, 1 September 2017.

Co-localised structural and functional changes in cocaine users are associated with recent cocaine consumption and potentially reversible
European Neuropsychopharmacology, 1 October, 2015.

Glutamatergic and neurometabolic alterations in chronic cocaine users measured with 1H‐magnetic resonance spectroscopy
Addiction Biology, 30 December 2014

FMR1 and mGluR5 as prospective molecular markers of sleep need in humans
Current Neuropharmacology, January 2014.

Prediction Of Psilocybin Response in Healthy Volunteers
PLOS ONE, 17 February 2012.

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Nature Reviews Neuroscience, 18 August 2010.

Reduced feed-back related negativity is associated with reinforcement-learning deficits in cocaine dependent patients
European Neuropsychopharmacology, August 2010.

Other publications

2024

2023

2022

2018

2016

2014

2013

2010

2008

Effects of the hallucinogenic 5-HT2A agonist psilocybin on object completion in humans
International Journal of Psychophysiology, September 2008

We’d like to
hear from you.

info@reconnect-labs.com

    About Us

    Investors

    Our Work

    ©2024 Reconnect Labs AG. All rights reserved.

    Contact-Block

    We’d like to hear from you.

    info@reconnect-labs.com

      About Us

      Investors

      Our Work

      ©2024 Reconnect Labs AG. All rights reserved.

      Contact-Block